Quan Zhang
Papers
1
Total Citations
5
H-Index
1
About
Quan Zhang is an emerging oncology researcher specializing in head and neck cancer, with a particular focus on HPV-associated oropharyngeal cancer (OPC) and innovative treatment de-escalation strategies. His most notable work centers on integrating immunotherapy with surgical and chemotherapeutic approaches to improve outcomes for patients with resectable oropharyngeal malignancies. Zhang's most cited contribution to date is a 2024 single-arm Phase II clinical trial investigating neoadjuvant sintilimab — an anti-PD-1 immune checkpoint inhibitor — combined with platinum-doublet chemotherapy, followed by transoral robotic surgery (TORS) in HPV-positive OPC patients. This work addresses one of the most pressing questions in the field: how to effectively reduce treatment intensity without compromising oncological control, thereby minimizing long-term toxicities that significantly affect patients' quality of life. By combining immunochemotherapy with the precision of robotic surgery, Zhang's research represents a forward-thinking, multidisciplinary paradigm for managing this increasingly prevalent cancer subtype. Though early in terms of citation accumulation, with 5 citations since publication, Zhang's research is positioned at the forefront of a rapidly evolving therapeutic landscape, making his work highly relevant for clinicians and researchers exploring cutting-edge, organ-preserving cancer treatment strategies.
Research Focus
Key Achievements
Top Papers
- 1